35610-09-4

Basic information

• Product Name: 2-AMINO-4-(DIMETHYLAMINO)-6-(METHYLTHIO)-1,3,5-TRIAZINE
• Synonyms: 2-AMINO-4-(DIMETHYLAMINO)-6-(METHYLTHIO)-1,3,5-TRIAZINE;N2,N2-dimethyl-6-(methylthio)-1,3,5-triazine-2,4-diamine
• CAS NO: 35610-09-4
• Molecular Formula: C6H11 N5 S
• Molecular Weight: 185.25
• Mol File: 35610-09-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-AMINO-4-(DIMETHYLAMINO)-6-(METHYLTHIO)-1,3,5-TRIAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4-(DIMETHYLAMINO)-6-(METHYLTHIO)-1,3,5-TRIAZINE(35610-09-4)
• EPA Substance Registry System: 2-AMINO-4-(DIMETHYLAMINO)-6-(METHYLTHIO)-1,3,5-TRIAZINE(35610-09-4)

Safety Data

• Hazardous Substances Data: 35610-09-4(Hazardous Substances Data)

Usage

Chemical compound type

Triazine derivative

Substituent groups

2-amino, dimethylamino, methylthio

Industrial applications

Intermediate in pharmaceutical, dye, and agrochemical synthesis

Uses

Reagent in organic chemistry reactions
Valuable in chemical and pharmaceutical processes
Of interest to researchers and industries for developing innovative products and processes

Upstream product

• 311-77-3 1,1-dimethylguanidine dihydrogensulfate 
• 10191-60-3 dimethyl N-cyanodithioiminocarbonate 

Downstream Products

• 1125365-14-1 N²,N²-dimethyl-N⁴-(2-propylphenyl)-1,3,5-triazine-2,4,6-triamine 

Relevant articles and documents

A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells

Mounting evidence suggests that metformin (N,N-dimethylbiguanide), a widely prescribed drug for the treatment of type II diabetes, exerts an anti-tumor effect on several cancers including breast cancer. Breast cancer has been estimated as one of the most commonly diagnosed types of cancer among women. In particular, triple-negative breast cancers are associated with poor prognosis and metastatic growth. In the present study, we synthesized a novel metformin derivative 5 (HL010183) and metformin salts, 9a, 9b, and 9c (metformin gamma-aminobutyric acid (GABA) salt, metformin pregabalin salt and metformin gabapentin salt), which exerted more potent inhibitory effects on the proliferation and invasiveness of Hs578T triple-negative breast carcinoma cells than metformin. Importantly, 5 showed approximately 100-fold more potent effects compared to metformin. In a triple-negative breast cancer xenograft model, 5 showed a comparable degree of inhibitory effect on in vivo tumor growth at the 100 mg/kg dose to that of metformin at 500 mg/kg. Our results clearly demonstrate that 5 exerts a potent anti-tumor effect both in vitro and in vivo, paving the way for a strategy for treatment of triple-negative breast cancer.